drugset / Trial / NCT02169453

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

NCT02169453

Phase 1 Completed 12 enrolled Bial - Portela C S.A.
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg (Sinemet® CR 100/25)

Timeline

Start
2008-10
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 25 mg Oral
Subject Opicapone Small molecule 50 mg Oral
Subject Opicapone Small molecule 100 mg Oral
Background Levodopa Small molecule

Indications